Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel
Prometheon Pharma says it has developed a breakthrough transdermal drug delivery system that can passively deliver large molecules like human growth hormone (which has a size of 2,200 daltons) across the skin.
Survey finds positive correlation between use of digital health tools and health status among diabetics
A survey of 2,000 Americans with diabetes found that those who regularly use digital tools and the Internet to manage their condition reported being in better health than those who do not.
A Sanofi-backed consortium has won clearance to run a virtual diabetes trial in Europe. The regulatory nod reportedly marks the first time European authorities have green-lit a clinical trial with full electronic informed consent.
San Diego's Viacyte is testing its artificial, lab-grown pancreas in three humans.
Study finds Medtronic MiniMed's insulin suspension feature cuts incidence of low blood sugar in diabetics
Medtronic touted data from a retrospective study of 20,973 diabetes patients finding that the Threshold Suspend feature of its MiniMed 530G system is helpful in reducing episodes of hypoglycemia, or low blood sugar.
Researchers from Bangalore's Indian Institute of Science have developed a novel microcapsule drug delivery mechanism for insulin using micro-shock waves that reduces the need for those oft-dreaded needles.
If your office has a pool on Sanofi's Afrezza launch--and come on, why not?--you're already tired of talking about Pfizer's failed version of an inhaled insulin, Exubera. You've entertained dubious comparisons between Afrezza, the needle-free version of a common insulin injection, and FluMist, the needle-free version of a common vaccine. You've made your list of reasons why other diabetes drugmakers aren't rushing around to come up with their own insulin inhalers.
Johnson & Johnson is partnering with Insuline Medical to register and distribute the Israeli company's InsuPad for promoting optimal absorption of insulin in diabetics by warming their injection site.
This year will be a rocky one for Baxter International as it aims to spin out its biopharmaceuticals business by mid-year to focus more closely on its diabetes-driven medical products. The new biopharma company already has been named Baxalta and its executives have been disclosed. Baxter declined to offer 2015 guidance for either of the companies.
The FDA has given its nod to the first glucose-monitoring app designed to be used with smartphones and other devices that can remotely track the health of a diabetic and "share" the information with up to 5 additional "followers."